Please note that the ANZCTR will be unattended from Friday the 17th of July to Monday the 20th of July 2020 inclusive. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02325791




Registration number
NCT02325791
Ethics application status
Date submitted
21/12/2014
Date registered
25/12/2014
Date last updated
6/11/2018

Titles & IDs
Public title
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Secondary ID [1] 0 0
R2222-RSV-1332
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Suptavumab 30 mg/kg
Treatment: Drugs - Placebo Matched to Suptavumab
Treatment: Drugs - Suptavumab 30 mg/kg- 1 Dose
Treatment: Drugs - Suptavumab 30 mg/kg - 2 Doses

Experimental: Part A: Suptavumab 30 mg/kg -

Experimental: Part B: Placebo Matched to Suptavumab -

Experimental: Part B: Suptavumab 30 mg/kg- 1 Dose -

Experimental: Part B: Suptavumab 30 mg/kg - 2 Doses -


Treatment: Drugs: Suptavumab 30 mg/kg
Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.

Treatment: Drugs: Placebo Matched to Suptavumab
Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.

Treatment: Drugs: Suptavumab 30 mg/kg- 1 Dose
Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.

Treatment: Drugs: Suptavumab 30 mg/kg - 2 Doses
Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Serum Concentration of Suptavumab Over Time - Part A was primarily designed to determine the pharmacokinetics (PK) of suptavumab in infants to inform the dose regimen used in Part B of the study. The study protocol specified the process and criteria for assessment of the dose. The dose used in Part B was to remain the same as Part A if the PK data up to Day 57 demonstrated that the individual PK observations were consistent with model-predicted concentrations, following age and body weight corrections.
Timepoint [1] 0 0
Day 1 through Day 150
Primary outcome [2] 0 0
Part B: Percentage of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Infection (Hospitalization or Outpatient Visit With Lower Respiratory Tract Infection [LRTI]) Up to Day 150 - A medically attended RSV infection defined as an infant with positive RSV test by Reverse-transcriptase polymerase chain reaction (RT-PCR) with any of following events: Hospitalized (on basis of assessment of admitting physician) for RSV infection or outpatient visit (emergency room [ER], urgent care [UC], or pediatric clinic visits [for either a sick or well visit]) with RSV lower respiratory tract infection (LRTI). An RSV LRTI in an infant: RSV proven respiratory infection (i.e positive RSV RT-PCR test) with parent(s)/guardian(s) report of cough/difficulty breathing, & with 1 of following signs of LRTI, as assessed by healthcare provider: - lower chest wall in drawing -hypoxemia (peripheral capillary oxygen saturation <95% breathing room air) - Wheezing/crackles. The 150-day efficacy assessment period: first study drug intake through the Day 150 visit.
Timepoint [2] 0 0
From first study drug administration up to Day 150
Secondary outcome [1] 0 0
Part A: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) - Any untoward medical occurrence in participants, who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed/worsened/became serious during on-treatment period (defined as time between the date of first study drug administration & date of end of study/last visit).Serious AE: Any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious & non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03(Grade 3 [severe] & Grade 4[life-threatening]) was used in this study to grade clinical AEs.
Timepoint [1] 0 0
Baseline through Day 150
Secondary outcome [2] 0 0
Part B: Serum Concentration of Suptavumab - Serum samples for drug concentration will be collected at pre-specified time points
Timepoint [2] 0 0
Day 29, 57, 85, 113 and Day 150 Post-dose
Secondary outcome [3] 0 0
Part B: Number of Participants With At Least One Positive Anti-Drug Antibody (ADA) Assay - ADA category of each participant was classified as pre-existing immunoreactivity (a positive ADA response at baseline with a <4-fold increase in titer for all post baseline samples), treatment-boosted (a positive response at baseline with at least one post baseline titer at >=4-fold the baseline titer), or treatment-emergent (TE [any positive post baseline assay response when baseline results were negative or missing]). TE ADA responses were further classified as persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 12-week post baseline period [based on nominal sampling time], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point), indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), or transient (not persistent/indeterminate, regardless of any missing samples).
Timepoint [3] 0 0
Day 1 through Day 150
Secondary outcome [4] 0 0
Part B: Percentage of Participants Hospitalized With Medically Attended RSV Infection or Outpatient Visit Lower Respiratory Tract Infection (LRTI) or Upper Respiratory Tract Infection (URTI) Up to Day 150 - A medically attended RSV infection was defined as an infant with a positive RSV test by RT-PCR with any of the following events: -Hospitalized (on the basis of the assessment of the admitting physician) for RSV infection - or Outpatient visit (ER, UC), or pediatric clinic visits [for either a sick or well visit]) with RSV LRTI. An RSV LRTI in an infant: RSV-proven respiratory infection (i.e, positive RSV RT-PCR test) with parent(s)/guardian(s) report of cough or difficulty breathing, and with 1 of the following signs of LRTI, as assessed by a healthcare provider: -Lower chest wall indrawing -Hypoxemia (peripheral capillary oxygen saturation <95% breathing room air) -Wheezing or crackles. The 150-day efficacy assessment period:first study drug intake through the Day 150 visit.
Timepoint [4] 0 0
From the first study drug administration up to Day 150

Eligibility
Key inclusion criteria
Key

1. Preterm, otherwise healthy male or female infant who is =6 months of age at the time
of the first dose (i.e., infant must be treated on or before their 6 month birthday)

2. Gestational age is =35 weeks, 6 days at birth

3. Parent(s) or legal guardian(s) of the infant is able to understand the study
requirements and willing to provide informed consent

Key
Minimum age
No limit
Maximum age
6 Months
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Eligible, recommended and have access to receive palivizumab per AAP or other local
guidelines, standard practice, or by their healthcare provider

2. History of CLD defined as requirement of supplemental oxygen for 28 days after birth

3. Known hemodynamically significant congenital heart disease

4. Known immunodeficiency, neuromuscular disease, or congenital abnormalities of the
airway

5. Known renal or hepatic dysfunction

6. Major congenital malformations, including congenital cleft palate, cytogenetic
abnormalities, or serious chronic disorders

7. Known or suspected impairment of immunological functions or autoimmune diseases

8. History of anaphylaxis

9. Previously received palivizumab or any other investigational RSV prophylaxis or
vaccine product

10. Previous reaction to IV immunoglobulin, blood products or other foreign proteins,
including vaccines and monoclonal antibodies

Note: Other inclusion and exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS
Recruitment hospital [1] 0 0
Regeneron Study Site - Hobart
Recruitment postcode(s) [1] 0 0
- Hobart
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
Nevada
Country [22] 0 0
United States of America
State/province [22] 0 0
New Hampshire
Country [23] 0 0
United States of America
State/province [23] 0 0
New Jersey
Country [24] 0 0
United States of America
State/province [24] 0 0
New York
Country [25] 0 0
United States of America
State/province [25] 0 0
North Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Ohio
Country [27] 0 0
United States of America
State/province [27] 0 0
Oklahoma
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
Tennessee
Country [32] 0 0
United States of America
State/province [32] 0 0
Texas
Country [33] 0 0
United States of America
State/province [33] 0 0
Utah
Country [34] 0 0
United States of America
State/province [34] 0 0
Virginia
Country [35] 0 0
United States of America
State/province [35] 0 0
West Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Wisconsin
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Sofia-Grad
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Stara Zagora
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Blagoevgrad
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Dobrich
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Gabrovo
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Lom
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Montana
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Pleven
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Plovdiv
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Ruse
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Silistra
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Sliven
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Vidin
Country [50] 0 0
Canada
State/province [50] 0 0
Alberta
Country [51] 0 0
Canada
State/province [51] 0 0
Nova Scotia
Country [52] 0 0
Canada
State/province [52] 0 0
Ontario
Country [53] 0 0
Chile
State/province [53] 0 0
Santiago
Country [54] 0 0
Denmark
State/province [54] 0 0
Aalborg
Country [55] 0 0
Denmark
State/province [55] 0 0
Hjorring
Country [56] 0 0
Denmark
State/province [56] 0 0
Naestved
Country [57] 0 0
Denmark
State/province [57] 0 0
Viborg
Country [58] 0 0
Finland
State/province [58] 0 0
Oulun Iaani
Country [59] 0 0
Finland
State/province [59] 0 0
Pori
Country [60] 0 0
Finland
State/province [60] 0 0
Turku
Country [61] 0 0
Germany
State/province [61] 0 0
Bochum
Country [62] 0 0
Germany
State/province [62] 0 0
Bramsche
Country [63] 0 0
Germany
State/province [63] 0 0
Bretten
Country [64] 0 0
Germany
State/province [64] 0 0
Frankenthal
Country [65] 0 0
Germany
State/province [65] 0 0
Freiburg
Country [66] 0 0
Germany
State/province [66] 0 0
Hamburg
Country [67] 0 0
Germany
State/province [67] 0 0
Herxheim
Country [68] 0 0
Germany
State/province [68] 0 0
Leipzig
Country [69] 0 0
Germany
State/province [69] 0 0
Mainz
Country [70] 0 0
Germany
State/province [70] 0 0
Mannheim
Country [71] 0 0
Germany
State/province [71] 0 0
Moenchengladbach
Country [72] 0 0
Germany
State/province [72] 0 0
Munich
Country [73] 0 0
Germany
State/province [73] 0 0
Sankt Augustin
Country [74] 0 0
Germany
State/province [74] 0 0
Wanzleben
Country [75] 0 0
Hungary
State/province [75] 0 0
Csongrad
Country [76] 0 0
Hungary
State/province [76] 0 0
Budapest
Country [77] 0 0
Hungary
State/province [77] 0 0
Gyula
Country [78] 0 0
Hungary
State/province [78] 0 0
Nyiregyhaza
Country [79] 0 0
Hungary
State/province [79] 0 0
Pecs
Country [80] 0 0
Hungary
State/province [80] 0 0
Veszprem
Country [81] 0 0
Netherlands
State/province [81] 0 0
Utrecht
Country [82] 0 0
New Zealand
State/province [82] 0 0
Manawatu-Wanganui
Country [83] 0 0
New Zealand
State/province [83] 0 0
North Island
Country [84] 0 0
New Zealand
State/province [84] 0 0
Wellington
Country [85] 0 0
Panama
State/province [85] 0 0
Ciudad de Panama
Country [86] 0 0
Puerto Rico
State/province [86] 0 0
San Juan
Country [87] 0 0
South Africa
State/province [87] 0 0
Gauteng
Country [88] 0 0
South Africa
State/province [88] 0 0
North - West
Country [89] 0 0
Spain
State/province [89] 0 0
Barcelona
Country [90] 0 0
Spain
State/province [90] 0 0
Granada
Country [91] 0 0
Spain
State/province [91] 0 0
La Coruna
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid
Country [93] 0 0
Spain
State/province [93] 0 0
Malaga
Country [94] 0 0
Spain
State/province [94] 0 0
Manises
Country [95] 0 0
Spain
State/province [95] 0 0
Santiago de Compostela
Country [96] 0 0
Spain
State/province [96] 0 0
Sevilla
Country [97] 0 0
Sweden
State/province [97] 0 0
Goteborg
Country [98] 0 0
Sweden
State/province [98] 0 0
Uppsala
Country [99] 0 0
Turkey
State/province [99] 0 0
Ankara
Country [100] 0 0
Turkey
State/province [100] 0 0
Istanbul
Country [101] 0 0
Turkey
State/province [101] 0 0
Izmir
Country [102] 0 0
Turkey
State/province [102] 0 0
Kocaeli
Country [103] 0 0
Ukraine
State/province [103] 0 0
Chernivets'ka Oblast'
Country [104] 0 0
Ukraine
State/province [104] 0 0
Dnipropetrovs'ka Oblast'
Country [105] 0 0
Ukraine
State/province [105] 0 0
Odes'ka Oblast'
Country [106] 0 0
Ukraine
State/province [106] 0 0
Vinnyts'ka Oblast'
Country [107] 0 0
Ukraine
State/province [107] 0 0
Kharkiv
Country [108] 0 0
Ukraine
State/province [108] 0 0
Kyiv
Country [109] 0 0
Ukraine
State/province [109] 0 0
Poltava
Country [110] 0 0
Ukraine
State/province [110] 0 0
Sumy
Country [111] 0 0
Ukraine
State/province [111] 0 0
Ternopil
Country [112] 0 0
Ukraine
State/province [112] 0 0
Zaporizhzhia
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Birmingham
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Hampshire
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Kent
Country [116] 0 0
United Kingdom
State/province [116] 0 0
London, City Of
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Manchester
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Belfast
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Glasgow
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Poole
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Reading
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Sheffield
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Stockton on Tees

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Regeneron Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and
immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days
gestational age who are no more than 6 months of age at the time of enrollment in their
respective geographic location. In order to optimize the potential benefit in this vulnerable
population, we conducted this study during the RSV season using dosing regimens that are
expected to be effective.
Trial website
https://clinicaltrials.gov/show/NCT02325791
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trial Management
Address 0 0
Regeneron Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications